Mayra Cruz-Rivera

Mayra Cruz-Rivera

Auto-generated profile, based on publicly available information

Mayra Cruz-Rivera

Departamento de Microbiologia y Parasitologia, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Mexico

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2019 in Apoptosis
Verified
Journal Article
Closed access
PDF file
ASAlejandro Schcolnik-Cabrera
Alejandro Schcolnik-Cabrera
BOBernardo Oldak
Bernardo Oldak
MJMandy Juárez
Mandy Juárez
MCMayra Cruz-Rivera
Mayra Cruz-Rivera
AFAna Flisser
Ana Flisser
FMFela Mendlovic
Fela Mendlovic

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MPMaria Victoria Preciado
Maria Victoria Preciado
PVPamela Valva
Pamela Valva
AEAlejandro Escobar-Gutierrez
Alejandro Escobar-Gutierrez
PRPaula Rahal
Paula Rahal
KRKarina Ruiz-Tovar
Karina Ruiz-Tovar
MCMayra Cruz-Rivera
Mayra Cruz-Rivera
Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors. Virus molecular evolution plays an important role in HCV transmission, disease progression and therapy outcome. The high degree of genetic heterogeneity characteristic of HCV is a key element for the rapid adaptation of the intrahost viral population to different selection pressures (e.g., host immune responses and antiviral therapy). HCV molecular evolution is shaped by different mechanisms including a high mutation rate, genetic bottlenecks, genetic drift, recombination, temporal variations and compartmentalization. These evolutionary processes constantly rearrange the composition of the HCV intrahost population in a staging manner. Remarkable advances in the understanding of the molecular mechanism controlling HCV replication have facilitated the development of a plethora of direct-acting antiviral agents against HCV. As a result, superior sustained viral responses have been attained. The rapidly evolving field of anti-HCV therapy is expected to broad its landscape even further with newer, more potent antivirals, bringing us one step closer to the interferon-free era.

1 February 2012 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
SFSalvador Fonseca-Coronado
Salvador Fonseca-Coronado
AEAlejandro Escobar-Gutiérrez
Alejandro Escobar-Gutiérrez
KRKarina Ruiz-Tovar
Karina Ruiz-Tovar
MCMayra Yolanda Cruz-Rivera
Mayra Yolanda Cruz-Rivera
PRPilar Rivera-Osorio
Pilar Rivera-Osorio
GVGilberto Vaughan
Gilberto Vaughan
The use of telaprevir and boceprevir, both protease inhibitors (PI), as part of the specifically targeted antiviral therapy for hepatitis C (STAT-C) has significantly improved sustained virologic response (SVR) rates. However, different clinical studies have also identified several mutations associated with viral resistance to both PIs. In the absence of selective pressure, drug-resistant hepatitis C virus (HCV) mutants are generally present at low frequency, making mutation detection challenging. Here, we describe a mismatch amplification mutation assay (MAMA) PCR method for the specific detection of naturally occurring drug-resistant HCV mutants. MAMA PCR successfully identified the corresponding HCV variants, while conventional methods such as direct sequencing, endpoint limiting dilution (EPLD), and bacterial cloning were not sensitive enough to detect circulating drug-resistant mutants in clinical specimens. Ultradeep pyrosequencing was used to confirm the presence of the corresponding HCV mutants. In treatment-naïve patients, the frequency of all resistant variants was below 1%. Deep amplicon sequencing allowed a detailed analysis of the structure of the viral population among these patients, showing that the evolution of the NS3 is limited to a rather small sequence space. Monitoring of HCV drug resistance before and during treatment is likely to provide important information for management of patients undergoing anti-HCV therapy.

1 April 2012 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
AEAlejandro Escobar-Gutiérrez
Alejandro Escobar-Gutiérrez
MVMauricio Vazquez-Pichardo
Mauricio Vazquez-Pichardo
MCMayra Cruz-Rivera
Mayra Cruz-Rivera
PRPilar Rivera-Osorio
Pilar Rivera-Osorio
JCJuan Carlos Carpio-Pedroza
Juan Carlos Carpio-Pedroza
GVGilberto Vaughan
Gilberto Vaughan
Here, we describe a transmission event of hepatitis C virus (HCV) among injection drug users. Next-generation sequencing (NGS) was used to assess the intrahost viral genetic variation. Deep amplicon sequencing of HCV hypervariable region 1 allowed for a detailed analysis of the structure of the viral population. Establishment of the genetic relatedness between cases was accomplished by phylogenetic analysis. NGS is a powerful tool with applications in molecular epidemiology studies and outbreak investigations.

1 March 2010 in Parasitology
Verified
Journal Article
Closed access
AFAna Flisser
Ana Flisser
GAGuillermina Avila-Ramirez
Guillermina Avila-Ramirez
Pablo MaravillaPablo Maravilla
Pablo Maravilla
FMF. Mendlovic
F. Mendlovic
SONIA LEON-CABRERASONIA LEON-CABRERA
SONIA LEON-CABRERA
DJD. E. Jimenez-Gonzalez
D. E. Jimenez-Gonzalez
SUMMARY: Neurocysticercosis is a public health problem in many developing countries and is the most frequent parasitic disease of the brain. The human tapeworm carrier is the main risk factor for acquiring neurocysticercosis. Since the parasite lodges only in the human intestine, experimental models ofTaenia soliumtaeniosis have been explored. Macaques, pigs, dogs, cats and rabbits are unsuccessful hosts even in immunodepressed status. By contrast, rodents are adequate hosts since tapeworms with mature, pregravid and, in some cases, gravid proglottids develop after infection. In this review, information that has been generated with experimental models of taeniosis due toT. soliumis discussed. Initially, the use of the model for immunodiagnosis of human taeniosis and evaluation of intervention measures is summarized. Next, descriptions of tapeworms and comparison of hamsters, gerbils and other mammals as experimental models are discussed, as well as data on the humoral immune response, the inflammatory reaction and the production of cytokines associated to Th1 and Th2 responses in the intestinal mucosa. Finally, evaluation of protection induced against the development of tapeworms by recombinantT. soliumcalreticulin in hamsters is summarized and compared to other studies.

1 January 2020 in Archives of Medical Research
Verified
Journal Article
Closed access
ASAlejandro Schcolnik-Cabrera
Alejandro Schcolnik-Cabrera
MJMandy Juárez
Mandy Juárez
BOBernardo Oldak
Bernardo Oldak
MCMayra Cruz-Rivera
Mayra Cruz-Rivera
AFAna Flisser
Ana Flisser
FMFela Mendlovic
Fela Mendlovic